The purposes of this work were to: (1) compare pharmacokinetic (PK) parameters for hydroxycarbamide in children receiving their first dose (HC new ) vs. those receiving chronic therapy (HC chronic ), (2) assess the external validity of a published PK dosing strategy, and (3) explore the accuracy of dosing strategies based on a limited number of HC measurements.
Introduction
Individuals with sickle cell anaemia (SCA; HbSS and HbSβ 0 thalassemia) suffer a wide spectrum of recurrent and debilitating clinical manifestations [1] . Hydroxycarbamide (hydroxyurea) is an approved therapy in the United States by the Food and Drug Administration (FDA) for adults and by the European Medicines Agency (EMA) for children and adults.
Hydroxycarbamide is a small, water-soluble molecule that remains non-ionized in the gastrointestinal tract and is approximately 100% bioavailable when administered orally [2] . Plasma concentrations are linear to the administered dose [3] , and at doses used to treat SCA, elimination is linear [4] with 50% excreted as the parent compound in urine [3] .
Despite FDA and EMA approval and several decades of experience with hydroxycarbamide in children, there remain several gaps in our knowledge regarding the pharmacokinetics (PK) of hydroxycarbamide. To date, published paediatric PK data have been obtained following a first-dose of hydroxycarbamide and limited data exist during chronic therapy [5, 6] . In these first-dose studies, a large degree of variation was observed in the absorption rate of hydroxycarbamide, and some variation in maximal drug concentration (C max ) and total drug exposure (AUC Inf ) was also noted [5, 6] .
In children treated with chronic hydroxycarbamide therapy escalated to maximum tolerated dose [MTD, defined by an absolute neutrophil count (ANC) goal of 2000-4000 × 10 6 l À1 ], a wide range (14.2-35.5 mg kg À1 day À1 ) of individual MTD doses are identified after an average of 8 months of dose escalation [6] [7] [8] , and exposure is not significantly altered with weight-based dosing schemes in children older than 2 years of age [9] . A recently proposed PK-guided dosing strategy based on plasma drug samples obtained 15-20 min, 50-60 min, and 3 h after the initial dose of hydroxycarbamide aimed to reduce the time required to reach MTD [10] ; however, the authors were unable to perform an internal or external validation of their findings.
The purposes of this work are as follows: (1) to compare PK parameters for hydroxycarbamide in children receiving their first-dose (HC new ) vs. those on chronic therapy (HC chronic ), (2) to assess the external validity of the published PK dosing strategy by Dong et al., and (3) to explore the accuracy of AUC predictions based on a different number of plasma drug concentration measurements.
Methods

Study design
Previously generated data from two prospective, open-label, single-dose, multicentre pharmacokinetic trials, 'Pharmacokinetics of Liquid Hydroxyurea in Pediatric Patients with Sickle Cell Anemia' (NCT01506544) and 'Single-Dose (SD) and Steady-State (SS) Pharmacokinetics of Hydroxyurea in Children and Adolescents with Sickle Cell Disease', conducted at eight medical centres in the United States were utilized for this analysis. Both trials received approval from local institutional ethics committees and participants provided informed consent.
Study population
Children (≤18 years of age) with either HbSS or HbSβ 0 thalassemia were eligible for participation. Inclusion criteria included being in a 'well' state (i.e., no acute SCA manifestations or other acute illness), weight of ≥10 kg, body mass index (BMI) ≥5th and ≤95th percentiles, and normal hepatic, renal and gastrointestinal function. Children were ineligible if they had a malignancy, received a recent blood transfusion, or had cytopenia noted on screening laboratory assessment. Additionally, children were excluded for concomitant medication usage that could potentially affect the analysis. This analysis compares children who had never been administered hydroxycarbamide (HC new ) with those that had been treated for ≥3 months at a stable dose (HC chronic ). All children received a physical examination and a medical history was taken, including a detailed medication history (prescription, over-the-counter medications and nutritional supplements). Individuals in the HC chronic cohort withheld their routine dose of hydroxycarbamide for 24 h prior to study drug administration. All children fasted for 8 h prior to receiving the study drug, and they abstained from food or drink 2 h post ingestion, when an age-appropriate diet was initiated. In order to minimize repeated venipuncture, all blood samples were obtained via a peripheral indwelling venous cannula (PIV). Patency of the PIV was maintained with infusion of sterile 0.9% sodium chloride.
Both 
Bioanalytical methods
For PK evaluations, whole blood (2 ml) was collected into heparinized tubes, inverted a minimum of 8-10 times, placed immediately on ice, and centrifuged at 750g for 10 min at room temperature. Plasma was separated and then stored at ≤À80°C until shipped to Children's Mercy Hospital on dry ice, where it was stored at ≤À80°C until analysis. Samples were analysed using a validated gas chromatography-mass spectrometry (GC-MS) technique that was linear from 0.1-100 μg ml À1 of hydroxycarbamide [11, 12] . The intra-and inter-assay coefficients of variation (CV) were consistently <10% across concentrations spanning the range of linearity [11] .
Noncompartmental PK methodology Plasma concentrations vs. time profiles were evaluated with a model-independent approach. The maximum plasma concentration (C max ) was obtained directly from the plasma concentration vs. time profile. The area under the plasma concentration vs. time curve (AUC 0-n ) was determined using the mixed log-linear rule. Extrapolation of the AUC to infinity (AUC inf ) was calculated by summation of AUC 0-n + C n /λ z , where C n represents the observed plasma concentration at the last quantifiable post-dose time point and λ z is the apparent terminal elimination rate constant (calculated from a curve fit of the apparent terminal elimination phase with 1/y weighting). The total plasma clearance (CL/F) and volume of distribution during the terminal phase (V z /F) were calculated from the AUC inf . The CL/F and V z /F were standardized for participant weight (CL/F/BW and V z /F/BW). To standardize for daily administered dose of hydroxycarbamide and difference in body mass, AUC inf and C max were divided by the daily prescribed dose (mg kg À1 ) (AUC inf /(Dose/BW), and
. This allowed comparison of those parameters between both cohorts (HC new and HC chronic ).
Statistical analysis
Noncompartmental PK modelling. Descriptive statistics are provided for continuous variables. Ninety-five per cent confidence intervals are provided for demographic and baseline laboratory parameters. Comparison of two groups was performed with either a two-sample t-test or exact Wilcoxon Rank Sum test, depending on normality of the data. Pearson and Spearman correlations were used to assess the relationship between two continuous variables, depending on the normality. Normality was tested using the Shapiro-Wilk test, and all hypothesis tests are considered significant at the α = 0.05 level. Analyses were conducted using SAS software version 9.3 (Cary, NC). Figure 1 , Figure 2B and Figure 3 were produced with GraphPad Prism v.6.07 (La Jolla, CA), and all others with SAS software.
Single time point sampling for prediction of drug exposure (internal model). Single post-dose plasma hydroxycarbamide concentrations were examined as a function of AUC inf to 
Figure 3
Boxplot summarizing the distribution of AUC inf prediction errors for five tested scenarios. Closed symbols represent naïve participants whereas open symbols represent chronically treated participants. Scenario 1 is based on the equation: 3.48*C 1.5hr + 24.3 using a single plasma hydroxycarbamide (HC) measurement obtained 1.5 h after ingestion. Scenario 2 is a previously published population prediction model [9] with no sampling. Scenario 3 is a MAP-Bayesian prediction based on a single plasma HC measurement at 1.5 h after ingestion. Scenario 4 is a previously reported MAP-Bayesian prediction based on three plasma HC measurements (15-20 min, 50-60 min, and 3 h) [10] . and a previously published model [9] . (5) Scenario 5. MAP-Bayesian predictions based on all available plasma measurements for a particular subject and a previously published model [9] .
Results
In total, 59 (HC new , n = 7; HU chronic , n = 52) children with HbSS at a mean (range) of 9. 
Noncompartmental PK results
Mean plasma concentrations (μg ml À1 ) and dose normalized mean plasma concentrations (μg ml À1 per 1 mg kg À1 ) vs. time (h) profiles of study participants in both the HC new and HC chronic cohorts are illustrated in Figure 1 and noncompartmental PK parameters are summarized in Table 1 . The mean time from administration of hydroxycarbamide to maximal plasma concentration (T max ) was 0.8 h but a wide range (0.2 to 2.0 h) was observed, corresponding to a large CV (61.5%). Mean maximal peak plasma concentrations (C max ) were similar (34.0 μg ml À1 ) in the HC new and HC chronic cohorts, but exhibited a broad range (15.2-65.6 μg ml À1 ) and a moderate degree of inter-patient variability with a CV of 30%. After dose/weight normalization, the C max was 1.4-fold higher in the HC new group compared to the HC chronic group (2.0 vs. 1.4 mg l À1 per 1 mg kg À1 dose, P = 0.025). There was less variability observed in post-peak plasma concentrations (C max ) and in dosenormalized plasma concentration (C max /dose) and those in hydroxycarbamide's elimination phase (i.e., concentrations at 4-12 h post-dose, Figure 1A and 1B). As expected from the visual depiction of the mean plasma concentration vs. time data (Figure 1A) , the mean elimination half-life for hydroxycarbamide did not differ between the HC new (2.1 h) and HC chronic (2.3 h) cohorts. The mean area under the plasma drug concentrationtime curve extrapolated to infinity (AUC inf ) or body exposure to hydroxycarbamide was similar between groups (107 μg h Limited sampling strategy for prediction of drug exposure (internal model)
In the entire cohort, AUC inf has a positive relationship with timed plasma concentrations, which becomes and maintains strong significance starting 90 min after the initial dose ( Figure 2A ). For example, 4 h after hydroxycarbamide ingestion, the fitted model is AUC inf = 35.24 + 6.81 × plasma concentration, which gives a coefficient of determination (R  2 ) for the linear regression model of 0.77 (i.e. 4 h after hydroxycarbamide ingestion, the plasma concentration explains about 78% of the variance of AUC inf ) ( Figure 2B ). The HC chronic group displays similar relationships where timed plasma concentrations are strongly association with AUC inf beginning at 90 min after the initial dose (and this association is maintained all the way until the eighth hour) (Figure 2A ). The HC new group displays a similar pattern except it is not as definitive. The first significant association between plasma concentrations and AUC inf starts at 4 h after the initial dose (R 2 = 0.7), and this relationship is maintained (Figure 2A ).
Validation of Bayesian estimators
Five different prediction scenarios (described in methods section above) were tested utilizing the maximum Bayesian estimation methodology described in the supplemental materials. The median prediction error (MDPE) and median absolute prediction error (MDAPE) of AUC predictions were low (<10% and <20%) and comparable across all scenarios ( Figure 3 and Table S1 ). In summary, the accuracy of prediction for drug exposure (AUC inf ) to hydroxycarbamide was not improved with the addition of single, multiple or numerous plasma concentrations when compared to population-based model predictions.
Discussion
In these prospectively collected data, we report the novel finding that dose-dependent PK parameters vary between children who were naïve to hydroxycarbamide and those treated for more than 3 months at a stable dosage. Specifically, the dose and weight-normalized peak plasma concentrations (C max /BW/dose) and drug exposure (AUC inf /DW/ dose) were lower in children treated with hydroxycarbamide for more than 3 months. We externally validated the published PK-guided dosing strategy by Dong et al. [10] ; however, we report that population predictions (without any plasma measurements) are accurate enough to make a basis for dose adjustments. In the five predictive scenarios we tested, there was little benefit to be gained from use of MAP Bayesian estimation with additional plasma measurements in terms of accuracy and precision of AUC predictions. Overall, the non-dose-normalized PK parameters for hydroxycarbamide from our study were comparable to other published populations [5, 6, 9] (Table S2 ). The apparent rate of absorption of hydroxycarbamide was rapid and showed a large degree of inter-individual variation, but was not affected by the dose administered or by the chronicity of therapy. The large degree of variation in absorption time has partially been explained by potential variations in transmembrane transporters that have been implicated in the absorption of hydroxycarbamide [6, 13] .
Wide ranges in individual peak plasma concentrations were observed, which is consistent with other reports in both younger and older children [5, 6, 9] . Children naïve to hydroxycarbamide achieved similar maximum plasma concentrations (C max ) and drug exposures (AUC inf ) compared to those treated with chronic therapy, albeit with a lower administered dose. With dose and body weight normalized, naïve children have a higher plasma concentration per dose administered (C max /(Dose/BW), drug exposure per dose administered (AUC inf /(Dose/BW)), and a lower clearance and volume of distribution normalized for body weight (CL/F/ BW). The mechanistic basis for these differences is not yet clear.
These novel observations have clinically relevant implications. First, the bioavailability (CL/F) of hydroxycarbamide changes with chronic therapy; specifically, given a fixed dose of hydroxycarbamide, drug exposure declines during chronic therapy. Understanding this relationship is vitally important and may provide insight into why paediatric patients appear to respond better to therapy when compared to adult populations [14, 15] . Second, understanding why bioavailability declines over time with exposure to hydroxycarbamide may provide some insight into why some individuals respond well to hydroxycarbamide and others respond poorly.
We were able to externally validate the PK-guided dose individualization strategy for hydroxycarbamide treatment for children with SCA proposed by Dong et al. [10] . We also evaluated the predictive performance of other scenarios utilizing MAP-based AUC predictions with none, one and 12 plasma samples and a direct relationship between AUC and HC concentration measurement 1.5 h after drug administration. The prediction error, MDPE and MDAPE were low (<10% and <20%) and comparable across all the tested scenarios. Our data suggest that the enrichment of PK sampling as performed in our study did not measurably add to the prediction accuracy attained with paediatric population-based dosing algorithms.
In summary, weight-normalized PK parameters suggest that apparent clearance of hydroxycarbamide is lower in children with chronic dosing compared to those that are naïve to therapy. Further work to investigate the mechanistic causes for changes in bioavailability over time in children treated with hydroxycarbamide should be pursued. and 8 (Time 9) hours post HC ingestion and the observed AUC inf . DV, dependent variable. Green line is the mean; red line median; dotted lines represent the 95% confidence interval. The goodness of fit was calculated using the coefficient of determination, the adjusted R
